TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01198535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03049020

Intervention type: PROCEDURE
Intervention: laparoscopic sacrocolpopexy
Description: standard laparoscopic sacrocolpopexy for prolapse treatment

Intervention type: PROCEDURE
Intervention: laparoscopic sacrocolpopexy
Description: standard laparoscopic sacrocolpopexy for prolapse treatment
Study: NCT02263729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Cozaar

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01713296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT00755261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
Study: NCT04981197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
Study: NCT02799121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReGenerCell™ Autologous Cell Harvesting Device
Study: NCT01586702

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient centered structured support program
Description: Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~* Measurement of risk factors~* Assessment of medication intake~* Monitoring of antithrombotic therapy~* Joint agreement of an individual target plan~Target values for risk factors:~* Blood pressure \< 140/85 mmHg (\<130/80 in diabetics), normal circadian profile~* HbA1c \<7.5%~* Nicotine abstinence~* LDL \< 100mg/dl (\< 70mg/dl in high risk patients)~* Physical activity ≥ 30min \>2 x / week~Targets for pharmaceutical treatment:~* Platelet inhibitors for strokes / TIA of arterial etiology~* Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~* Cumarins (INR 2-3) or new oral anticoagulants in AF patients~* Statin treatment in patients with LDL \>100mg/dl~Intervention strategies:~• According to Motivational Interviewing
Study: NCT01007383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847
Description: First in man

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847
Description: First in man

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 27847
Description: First in man
Study: NCT03937141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADU-S100
Description: intratumoral
Study: NCT02495766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-MC-ALPHA
Description: Single infusion
Study: NCT03116295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone (OPC)
Description: Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone (OPC)
Description: Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
Study: NCT02495766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-MC-ALPHA
Description: Single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single infusion
Study: NCT01420341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-trimoxazole 12
Description: Receive treatment with co-trimoxazole for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 20
Description: Receive treatment with co-trimoxazole for 20 weeks.
Study: NCT01044368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
Study: NCT03999528

Intervention type: DIAGNOSTIC_TEST
Intervention: 14-3-3η Protein assay
Description: blood sampling for assessment of serum 14-3-3η Protein

Intervention type: DIAGNOSTIC_TEST
Intervention: 14-3-3η Protein assay
Description: blood sampling for assessment of serum 14-3-3η Protein
Study: NCT05253144

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT04437797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Extrusion
Description: The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implant Placement
Description: The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
Study: NCT01196377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Nebulized albuterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Nebulized albuterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Nebulized albuterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Nebulized albuterol
Study: NCT02975531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator's construction
Description: Model to build the mold for the simulator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model Features
Description: Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parameterization technique
Description: Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator training
Description: Training of pompage technique using the simulator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Evaluation
Description: Evaluation of volunteers from GE group before and after training with the simulator.
Study: NCT02963129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Mupirocin ointment in the nose for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment in the nose for 5 days
Study: NCT03534739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Massage
Description: Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Touch Massage
Description: Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coldpressor
Description: Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
Study: NCT00064415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol
Description: Arformoterol inhalation solution, 50 mcg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol MDI, 42 mcg BID
Study: NCT04779281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Salts supplemented with L. Rhamnosus GG
Description: A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Salts only
Description: A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
Study: NCT02875873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte
Description: Plasma-Lyte will be used for fluid expansion and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte
Description: Plasma-Lyte will be used for fluid expansion and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline 0.9%
Description: Saline 0.9% will be used for fluid expansion and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline 0.9%
Description: Saline 0.9% will be used for fluid expansion and maintenance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow infusion speed
Description: Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow infusion speed
Description: Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Infusion Speed
Description: Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Infusion Speed
Description: Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
Study: NCT04123249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation；
Study: NCT02495766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single infusion
Study: NCT03017742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter
Study: NCT00537342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with modified extract of O. europaea pollen
Description: Sublingual (2 drops daily during 2 months)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Immunotherapy with modified extract of O. europaea pollen
Description: Sublingual (2 drops daily during 2 months)
Study: NCT00605488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: novel PET tracer FACBC
Description: Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
Study: NCT02614183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01376492

Intervention type: OTHER
Intervention: Functioning assessment
Description: The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)

Intervention type: OTHER
Intervention: Quality of sleep assessment
Description: The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
Study: NCT02771379

Intervention type: DRUG
Intervention: Idebenone
Description: Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
Study: NCT04481685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-450
Description: 50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill will be taken twice daily preferably spaced 12 hours apart.
Study: NCT02251236

Intervention type: DRUG
Group type: OTHER
Intervention: Stribild
Description: To be administered orally, once daily with food.

Intervention type: DRUG
Group type: OTHER
Intervention: Stribild
Description: To be administered orally, once daily with food.

Intervention type: DRUG
Group type: OTHER
Intervention: Genvoya
Description: To be administered orally, once daily with food.

Intervention type: DRUG
Group type: OTHER
Intervention: Genvoya
Description: To be administered orally, once daily with food.

Intervention type: DRUG
Group type: OTHER
Intervention: Genvoya
Description: To be administered orally, once daily with food.
Study: NCT01407055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation Manipulation Intervention
Description: The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
Study: NCT01303250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balanced 6% hydroxyethylstarch 130/0.4
Description: Fluid administration and optimization based on cardiac output findings during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: balanced crystalloid
Description: Fluid administration and optimization based on cardiac output findings during surgery.
Study: NCT04507568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.
Study: NCT01636245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: three consecutive lots of EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: three consecutive lots of EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: three consecutive lots of EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, two doses, 28 days interval
Study: NCT03161613

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT01783132

Intervention type: DEVICE
Group type: OTHER
Intervention: NIOX MINO
Description: Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
Study: NCT02469155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04347057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed bathing with 2% CHG solution
Description: Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with CHG solution for each period. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed bathing with 2% CHG solution
Description: Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with CHG solution for each period. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed bathing with soap and water
Description: Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with soap and water. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions. During control period, patients were washed with soap and then rinsed with water, and dried with disposable towels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed bathing with soap and water
Description: Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with soap and water. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions. During control period, patients were washed with soap and then rinsed with water, and dried with disposable towels
Study: NCT00599274

Intervention type: DRUG
Intervention: Interferon beta-1a
Description: injection once a week

Intervention type: DRUG
Intervention: Interferon beta-1a
Description: injection three times a week
Study: NCT02718261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% (matching placebo)
Study: NCT03681535

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.